Letter sent to Harvard University President Lawrence Bacow
June 3, 2022
Sent via certified mail and email to email@example.com
Dr. Lawrence Bacow, President
Cambridge, MA 02138
Dear Dr. Bacow,
We are writing to notify you of recently available information prompting concern that fraud has been committed by Pfizer and by the FDA in the development and continued distribution of Pfizer’s Covid-19 vaccine. Given that Harvard University mandates Covid-19 vaccination for students as a condition of enrollment, it is incumbent upon you to be fully informed about the safety and efficacy of these vaccines and the claims of fraud that call both into question.
If fraud or willful misconduct is proven, the manufacturers and those involved in the distribution or mandating of the vaccines will lose immunity from liability granted to them under the existing EUA and the PREP act.
We urge you to further investigate. We believe that once you do, you will see how continued Covid-19 vaccine mandates jeopardize the safety of your students and the reputation of your institution.
The new information consists of Pfizer’s biological product file used to obtain FDA approval of Comirnaty and data from the insurance industry showing a huge rise in excess deaths in Millennial and Gen X populations concurrent with the implementation of vaccine approvals and mandates. The excess death data is raising concerns in the insurance industry and on Wall Street. We are also including timely news about product safety, given the FDA’s recent restriction of the Johnson & Johnson vaccine due to blood clotting concerns.
Below we give a brief overview of each category and starting points for further inquiry. We are standing by to provide you with additional information or to connect you to scientists, lawyers and investors who are reviewing the current and evolving data.
Pfizer Biological Product File – background and highlights:
The Public Health and Medical Professionals for Transparency (PHMPT) is a nonprofit group made up of public health professionals, medical professionals, scientists, and journalists. The group exists solely to obtain and disseminate the data relied upon by the FDA to license Covid-19 vaccines. Four days after the Pfizer Covid-19 vaccine was approved for children over 16, this group submitted a Freedom of Information Act for all data within Pfizer’s Covid-19 vaccine biological product file. When the FDA asked for 75 years to release that data, PHMPT sued to obtain it and won. Beginning in March 2022, the public has access to Pfizer’s clinical trial data, which is being downloaded in batches monthly. You can find the document releases to-date here.
Thousands of volunteers including scientists, statisticians, doctors, and lawyers continue to examine these downloads and publish their findings. For ready reference, below are just a few of the findings of greatest concern that call into question the safety and efficacy of the Pfizer product and support a thesis of fraud:
- Pfizer failed the all-cause mortality endpoint in their unprecedentedly short 28-day clinical trial. In brief, more people died in the vaccinated group than in the placebo group. This was known yet has still not been widely disclosed to the public.
- The CDC talking point that vaccines stopped transmission was based on no data, as this metric was not evaluated during Pfizer’s clinical trials. Pfizer and the FDA knew this yet did not disclose it to the public.
- Pfizer and the FDA knew as early as November 2020 that Pfizer’s clinical trials showed
- Vaccine failure
- Waning vaccine efficacy
- A baseline condition for granting a product Emergency Use Authorization is that it must be safe and effective. The data showed that the products are not effective. Yet, based on FDA approval, the CDC promoted them as such. From the initial roll-out in December 2020 through April 1, 2021, the public health messaging was that if you received the shot, you could not get infected and could not transmit the virus. The Pfizer documents are proof that they and the FDA colluded to lie to the American people and the CDC created false public health narratives based on these lies.
- Pfizer and the FDA most likely knew in May 2021 that the vaccines caused heart damage in teenagers based on a paper that was already in peer review at that time. The FDA approved the product for teenagers in June 2021 yet did not disclose this risk factor to consumers until August. During that time, all those who received this product did not have informed consent. Parents were not made aware of this known potential risk to their children.
- Brook Jackson, a regional director employed by Pfizer sub-contractor Ventavia Research Group, came forward in September 2020 with documented evidence that the company falsified data, unblinded patients and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial conducted by Ventavia. Her findings call into question the integrity of not only Ventavia’s results but of all of the results from Pfizer’s other trial sites and the entire clinical trial. Further information is available in The British Medical Journal.
Excess death data and the insurance industry:
In December 2021, Midwest insurer One America CEO Scott Davidson disclosed a 40% increase in excess deaths over pre-pandemic levels in the working-age (18-64) population in the third quarter. Putting the number into context Davidson said, “The data is consistent across every player in this business . . . Just to give you an idea of how bad that is, a three-sigma or a one-in-200-year catastrophe would be a 10 percent increase over pre-pandemic. So 40 percent is just unheard of”. Other major insurers have subsequently reported increases in death claims ranging from 21–57 % over expected levels. Most of these deaths are not Covid-19 deaths. Long-term disability claims are also seeing an uptick.
These reports prompted a former institutional investor who was a #1 ranked Wall Street sell-side insurance analyst to confirm the numbers using CDC reported data. His findings, independently confirmed by others, show the spikes in excess deaths are related to the timing of vaccine approvals and mandates. This data is prompting concern at insurance and reinsurance companies, who will bear the financial brunt of this unexpected and unprecedented rise in mortality. It is raising questions about the safety of the Covid-19 vaccines in the investment community and beyond.
Of related interest is Pfizer’s amendment in February of its business risk disclosures in its Q4 2021 earnings report. The changes from the Q3 2021 report language center around disclosures of unfavorable safety data and “further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection”.
It is likely that neither Pfizer nor the FDA anticipated the court-compelled release of their clinical trial and post-marketing surveillance data and the subsequent public scrutiny of it.
Additional product safety concerns:
The FDA announced on May 5 that they were restricting use of the Johnson & Johnson Covid-19 vaccine due to the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets. The decision to restrict was based on 60 reported cases and 9 fatalities. The Pfizer and Moderna vaccines also have serious risks and fatalities associated with them including but not limited to blood clots and myocarditis in college-aged populations. These are shown in Pfizer’s post-marketing surveillance data and in the CDC’s Vaccine Adverse Event Recording System (VAERS). As of April 29, 2022, there were approximately 1.2 million reports of adverse events following Covid-19 vaccination including more than 18,056 reports of deaths following the Pfizer vaccine, and 7,223 following the Moderna vaccine. Logic demands that Pfizer and Moderna products be restricted immediately as well. Why have they not been? Further, a recent Danish review of all three products in preprint in The Lancet showed that the J&J reduced all-cause mortality but that Pfizer and Moderna did not and may have increased it. Given all this, it is reasonable to think that Pfizer and Moderna products could be restricted or discontinued very soon due to safety concerns. This might well trigger a much higher level of scrutiny of the now-publicly available Pfizer data and the actions of our public health institutions. How would such a situation impact institutions such as yours that continue to mandate the products while knowing such risks exist?
One last thing to consider is the nature and associated secrecy of the contracts that Pfizer forced upon governments as conditions of sale and distribution of their Covid-19 vaccines in their respective countries. A review of some of these contracts can be found here. Terms included such things as the waiving of sovereign immunity, countries assuming full liability in the event that Pfizer was shown to have used another entity’s intellectual property, and that Pfizer be held harmless in the event of injury or death from the products. Why would a company require such terms if it knew its conduct and its products were sound?
We trust this information has been useful and that you will investigate this matter fully. We urge you to end your vaccine mandates to protect Harvard University’s students, reputation, and, in the event that fraud is proven, potentially your endowment.
No College Mandates
No College Mandates is a coalition of thousands of concerned students, parents, professors, staff, and community members working to end college Covid-19 vaccination mandates and restore medical choice on college campuses.
Health Freedom Defense Fund
Health Freedom Defense Fund is a 501(c)(3) non-profit which seeks to protect and advance health freedom, educate Americans on informed consent, advocate for human rights and bodily autonomy for all people, and legally challenge unethical mandates, laws, and policies when necessary.
cc. Dr. Alan Garber, Provost
Ms. Diane Lopez, VP and General Counsel
Mr. Michael Monaghan, Director of Risk Management and Audit Services
Mr. Paul Choi, President, Harvard Board of Overseers
Mr. Timothy R. Barakett, Harvard Corporation Fellow
Mr. Kenneth I. Chenault, Harvard Corporation Fellow
Mr. Mariano-Florentino (Tino) Cuéllar, Harvard Corporation Fellow
Mr. Paul J. Finnegan, Harvard Corporation Treasurer and Fellow
Mr. William F. Lee, Harvard Corporation Senior Fellow
Dr. Biddy Martin, Harvard Corporation Fellow
Ms. Karen Gordon Mills, Harvard Corporation Fellow
Ms. Diana L. Nelson, Harvard Corporation Fellow
Ms. Penny Pritzker, Harvard Corporation Fellow
Mr. David M. Rubenstein, Harvard Corporation Fellow
Dr. Shirley M. Tilghman, Harvard Corporation Fellow
Mr. Theodore V. Wells, Jr., Harvard Corporation Fellow